How Good are Experts at Predicting the Market?

 


Last Year’s Market Predictions – What was the Final Batting Average?

 

Here’s a look back to see how the experts’ projections stood up in the topsy turvy year of 2020. We unearthed a December 19, 2019 article on Yahoo by Emily McCormick that highlighted the 2020 predictions of 23 Wall Street strategists. Each provided a target for the S&P 500 for the year ending 2020, along with additional commentary. The majority of the reports were issued in the first two weeks of December 2019. The data and comments we are citing come directly from that article.

What Actually Occurred

Before we get into the observations, we would note the S&P 500 closed at 3,230.78 on December 31, 2019. It closed higher at 3,756.07 on December 31, 2020. That’s a 16.2% annual return. Obviously, that return masks a wild intra-year ride, as the S&P 500 bottomed out on March 23 at 2,191 (intra-day) and closed the day at 2,237.40. For those investors with perfect timing, the S&P 500 rose 71.6% from its March 23 lows to the end of 2020.

Forecasts

In mid-December 2019, the average of the 23 estimates for the 2020 closing S&P 500 index was 3,332, off by nearly 13% relative to what the actual closing level was in 2020. Obviously, COVID and all its implications were not factored into the prognosticators’ forecasts. The range of forecasts went from 3,000, implying a down year in 2020, to as high as 3,600, which was still more than 4% below the S&P 500’s actual performance. The 3,600 prediction was a true outlier as the next closest estimate was 3,450. If we looked at a distribution of the forecasts, nine of the 23 were below the 3,332 average.

So, in the year of wild market swings, impacted by a 100-year pandemic, the experts were clearly off by a significant factor.

There were recurring themes within the commentary from the strategists as to what could impact the stock market in 2020. As one would expect, the election, China/U.S. relations, especially as related to trade, and an accommodative Federal Reserve were mentioned prominently by most strategists.

Forecasts vs. Actual

But some of the other predictions did not play-out as well. For example, in assembling their forecast, most of the strategists predicted higher earnings for the S&P 500. In fact, many of the projections for S&P 500 earnings were in the $165-$175 range; when fully reported, earnings are actually expected to have dropped year-over-year to the $135 level from $163 in 2019.

Some strategists favored non-U.S. markets, predicting better returns overseas. But according to Yardeni Research, the MSCI Share price index for the U.S. was up 19.2% in 2020, well above the All Country Index of 14.3%. And in fact, the U.S. market outperformed each of the five other indexes: European Market, Japan, U.K., and Emerging Markets. To be fair, the Asian Emerging Market significantly outperformed the U.S., but the overall Emerging Markets average was held back by poor performance in Latin America.

Another prediction raised was a move from Growth stocks to Value stocks. This switch does not appear to have happened as much of the upswing in the Index was driven by the growth-oriented FAANGM stocks during much of the year.

One interesting prediction that seems to have come true was by
Julian Emanuel of BTIG, who stated that with “zero-fee online trading, 2020 could be the year the public falls in love with stocks again.” The rise of Robinhood seems to agree with this statement.

Take-Away

It is often said, with good reason, that it is easier to predict the stock market when given a longer time horizon, perhaps even ten years or longer. The reason is the smoothing that the impact of time and average growth has on the outlier years. Predicting what will happen tomorrow involves so many unknown influences that “experts” are befuddled by the exercise daily.

The predictions made in 2019 concerning the earnings of the S&P 500 were off in terms of direction (earnings were down, not up). This would cause one to expect lower stock prices than predicted. Obviously this didn’t happen either.  While knowledge and understanding of what market strategist predictions are is a useful guide to our own risk/reward assessments, it’s helpful to remember as we enter the new year and new sets of market predictions that the stock market is like a talented major league pitcher – they’re able to get even the most gifted hitters out more often than not.  Yet, we can still improve our own skills by observing the big bats go up against them. 

 

Suggested Reading:

Investment of Excess Corporate Cash

The Expected Pace of the IPO Market in 2021

What do Investors Look At?

 

Are you subscribed to Channelchek’s active YouTube channel?

 

Sources:

Emily McCormick/Yahoo Finance 12/19 Article

 

NobleCon17 Presenting Companies List

NobleCon17 Presenting Company Schedule
January 19 & 20, 2021

Complete rebroadcast catalog now available on Channelchek!

Two days of public companies presenting, followed by Q&A sessions moderated by accredited research analysts. Four panels featuring key opinion leaders. Virtual Networking. For more information on NobleCon17, go to nobleconference.com.

   

Click the logos to view advanced market data and recent news for each company
All times listed are Eastern Standard Time

Tuesday January 19, 2021


Healthcare Panel
Track 1 – 8:35am
 

Transportation Panel
Track 2 – 8:35am
 

XBIO (Nasdaq)
Track 1 – 9:45am
 

OS Therapies
Track 2 – 9:45am
 

ENCUF (OTCQB)
Track 3 – 9:45am
Watch the Preview

GLVMF (OTCQX)
Track 4 – 9:45am
Watch the Preview

CLBS (Nasdaq)
Track 1 – 10:30am
Watch the Preview

III (Nasdaq)
Track 2 – 10:30am
Watch the Preview

IPOOF (OTCQX)
Track 3 – 10:30am
Watch the Preview

UUUU (NYSE)
Track 4 – 10:30am
 

HSDT (Nasdaq)
Track 1 – 11:15am
Watch the Preview

OSS (Nasdaq)
Track 2 – 11:15am
Watch the Preview

GEVO (Nasdaq)
Track 3 – 11:15am
Watch the Preview

ELYGF (OTCQX)
Track 4 – 11:15am
Watch the Preview

LCTX (NYSE)
Track 1 – 12:00pm
Watch the Preview

ORN (NYSE)
Track 2 – 12:00pm
 

CPST (Nasdaq)
Track 3 – 12:00pm
Watch the Preview

EXK (NYSE)
Track 4 – 12:00pm
Watch the Preview

Currently Scheduling
Track 1 – 12:45pm
 

LMB (Nasdaq)
Track 2 – 12:45pm
Watch the Preview

INDO (NYSE)
Track 3 – 12:45pm
Watch the Preview

SMTS (NYSE)
Track 4 – 12:45pm
Watch the Preview

CTXR (Nasdaq)
Track 1 – 1:30pm
 

CMTL (NasdaqGS)
Track 2 – 1:30pm
 

CMLS (Nasdaq)
Track 3 – 1:30pm
 

AUIAF (OTCQB)
Track 4 – 1:30pm
Watch the Preview

COCP (Nasdaq)
Track 1 – 2:15pm
Watch the Preview

REKR (Nasdaq)
Track 2 – 2:15pm
Watch the Preview

TPCO (Nasdaq)
Track 3 – 2:15pm
 

AUXXF (OTCQX)
Track 4 – 2:15pm
Watch the Preview

CURR (OTCQB)
Track 1 – 3:00pm
 

TAALF (OTCQX)
Track 2 – 3:00pm
Watch the Preview

Playboy Enterprises
Track 3 – 3:00pm
Watch the Preview

CHKKF (OTCQB)
Track 4 – 3:00pm
Watch the Preview

GNPX (Nasdaq)
Track 1 – 3:45pm
Watch the Preview

FLYLF (OTCQX)
Track 2 – 3:45pm
 

EVC (NYSE)
Track 3 – 3:45pm
 

NTGSF (OTCQX)
Track 4 – 3:45pm
Watch the Preview

JAGX (Nasdaq)
Track 1 – 4:30pm
Watch the Preview

JETMF (OTCQB)
Track 2 – 4:30pm
Watch the Preview

TSQ (NYSE)
Track 3 – 4:30pm
 

NRGOF (OTCQB)
Track 4 – 4:30pm
Watch the Preview

RCAR (OTCPK)
Track 1 – 5:15pm
 

PANL (Nasdaq)
Track 2 – 5:15pm
 
 
Natural Resources Panel
Track 4 – 5:15pm

Wednesday January 20, 2021


ELDN (Nasdaq)
Track 1 – 9:00am
 

PTPI (Nasdaq)
Track 2 – 9:00am
 

MEEC (OTCQB)
Track 3 – 9:00am
 

NMGRF (OTCQX)
Track 4 – 9:00am
 

VIVXF (OTCQB)
Track 1 – 9:45am
Watch the Preview

MIND (NasdaqGS)
Track 2 – 9:45am
Watch the Preview

SSP (NasdaqGS)
Track 3 – 9:45am
 

NKORF (OTCPK)
Track 4 – 9:45am
Watch the Preview

OCGN (Nasdaq)
Track 1 – 10:30am
Watch the Preview

GNK (NYSE)
Track 2 – 10:30am
 

ACCO (NYSE)
Track 3 – 10:30am
 

LODE (NYSE)
Track 4 – 10:30am
Watch the Preview

CRPOF (OTCQX)
Track 1 – 11:15am
 

INSW (NYSE)
Track 2 – 11:15am
 

DLHC (Nasdaq)
Track 3 – 11:15am
Watch the Preview

MUNMF (OTCQB)
Track 4 – 11:15am
Watch the Preview

AEZS (Nasdaq)
Track 1 – 12:00pm
 

GLDD (NasdaqGS)
Track 2 – 12:00pm
Watch the Preview

GMBL (Nasdaq)
Track 3 – 12:00pm
Watch the Preview

STTDF (OTCQB)
Track 4 – 12:00pm
Watch the Preview

KRBP (Nasdaq)
Track 1 – 12:45pm
Watch the Preview

SHIP (Nasdaq)
Track 2 – 12:45pm
Watch the Preview

Private Company
Track 3 – 12:45pm
Watch the Preview

JAGGF (OTCPK)
Track 4 – 12:45pm
Watch the Preview

AYLA (Nasdaq)
Track 1 – 1:30pm
 

PXS (Nasdaq)
Track 2 – 1:30pm
 

FAT (Nasdaq)
Track 3 – 1:30pm
Watch the Preview

VGZ (NYSE)
Track 4 – 1:30pm
Watch the Preview

STMH (OTCQX)
Track 1 – 2:15pm
 

EGLE (NasdaqGS)
Track 2 – 2:15pm
Watch the Preview

SALM (Nasdaq)
Track 3 – 2:15pm
Watch the Preview

GLDRF (OTCQB)
Track 4 – 2:15pm
Watch the Preview

VNRX (NYSE)
Track 1 – 3:00pm
 

EDRY (Nasdaq)
Track 2 – 3:00pm
 

VYGVF (OTCQB)
Track 3 – 3:00pm
Watch the Preview

GGIFF (OTC)
Track 4 – 3:00pm
 

Adaptive Phage
Track 1 – 3:45pm
 

NXTTF (OTCQB)
Track 2 – 3:45pm
Watch the Preview

LSYN (OTCQB)
Track 3 – 3:45pm
 

FTK (NYSE)
Track 4 – 3:45pm
 

ONTX (Nasdaq)
Track 1 – 4:30pm
Watch the Preview

CXW (NYSE)
Track 2 – 4:30pm
 

GTBAF (BUSXF)
Track 3 – 4:30pm
 

GTBAF (OTCQX)
Track 4 – 4:30pm
 
 
ESEA (Nasdaq)
Track 2 – 5:15pm
 
 
Track 4 – 5:15pm

InvestorBrandNetwork is the Media Sponsor of NobleCon
InvestorWire is the Official NewsWire of NobleCon

Release – Sigyn Therapeutics (SIGY) – Reports Results of Pilot Study to Address Inflammatory CytoVesicles

 


Sigyn Therapeutics™ Reports Results of Pilot Study to Address Inflammatory CytoVesicles

 

Sigyn Therapy™ is a Candidate to Treat Life-Threatening Inflammatory Conditions That Are Not Addressed with Drug Therapies

SAN DIEGO, Jan. 06, 2021 (GLOBE NEWSWIRE) — via NewMediaWire — Sigyn Therapeutics, Inc. (OTCMarkets: SIGY), a medical technology company whose focus is the treatment of life-threatening inflammatory conditions precipitated by Cytokine Storm Syndrome (the Cytokine Storm), today announced the results of an in vitro pilot study that successfully modeled the ability of Sigyn Therapy™ to address CytoVesicles that transport inflammatory cytokine cargos in the bloodstream.

Cytokine Storm Syndrome is an excessive response of the immune system that is induced by infectious and non-infectious conditions. A hallmark indicator of Cytokine Storm Syndrome is the excessive or uncontrolled release of pro-inflammatory cytokines, which can lead to multiple organ failure and cause death. The annual market opportunity to address Cytokine Storm related indications exceeds $20 billion and includes sepsis, the most common cause of hospital deaths worldwide. Virus-induced Cytokine Storm Syndrome is a leading cause of death resulting from severe SARS-CoV-2 (COVID-19) infections.

Sigyn Therapy is a proprietary blood purification technology designed to overcome the limitations of previous drug and device candidates to treat acute inflammatory conditions. Incorporated within Sigyn Therapy is a cocktail of adsorbent components with unique binding and capture characteristics to optimize the broad-spectrum depletion of inflammatory targets from the bloodstream. These targets include pro-inflammatory cytokines, endotoxin and CytoVesicles (extracellular vesicles that transport inflammatory cytokine cargos) that participate in concert with freely circulating cytokines to further escalate the Cytokine Storm. CytoVesicles are an important yet previously elusive target as they can be 20-60 times larger than cytokines themselves.

In the in vitro pilot study, 104nm liposomes were utilized as a model system to assess the ability of Sigyn Therapy’s adsorbent components to deplete CytoVesicles from human blood plasma. After a two-hour interaction with Sigyn’s adsorbent components, liposome concentrations in human blood plasma were reduced ~90%. Previously published studies have validated liposomes as a model for the isolation of extracellular vesicles from blood based on the similarity of their size and structural characteristics.

“When we designed Sigyn Therapy, we envisioned a device that could be broadly deployed by the medical community, yet also have expansive first-in-industry capabilities that offer to improve patient outcomes,” stated Jim Joyce, Chairman and CEO of Sigyn Therapeutics. “When considering our previous report that Sigyn Therapy™ clears both endotoxin and inflammatory cytokines from human blood plasma, the observation from our CytoVesicle pilot study further reinforces the potential for our vision to become a therapeutic reality.”

Sigyn Therapy is a single-use device designed for use on the established infrastructure of dialysis and CRRT machines already located in hospitals and clinics worldwide. On December 1, 2020, the Company reported the results of an in vitro study that validated the ability of Sigyn Therapy to simultaneously reduce the presence of endotoxin and relevant pro-inflammatory cytokines, which included Interleukin-1 Beta (IL-1B), Interleukin-6 (IL-6) and Tumor Necrosis Factor alpha (TNF-a). Endotoxin (lipopolysaccharide or LPS) is a potent mediator implicated in the pathogenesis of sepsis and septic shock. The dysregulated over-production of IL-1B, IL-6 and TNF-a can lead to organ failure and cause death.

An objective of the study was to rebalance elevated cytokine levels and optimize the elimination of endotoxin from human blood plasma. The study was conducted in triplicate over four-hour time periods with a pediatric version of Sigyn Therapy. Average reduction of endotoxin load peaked at 83% during the studies. The average reduction of IL-1B was 69%, IL-6 reduction was 59% and TNF-a reduction was 57% during the four-hour studies.

The resulting data from each of these studies will be incorporated into an Investigational Device Exemption (IDE) that Sigyn Therapeutics plans to submit to the United States Food and Drug Administration (FDA) in 2021.

About Sigyn Therapeutics

Sigyn Therapeutics™ is a development-stage therapeutic technology company headquartered in San Diego, California USA. Our focus is directed toward a significant unmet need in global health; the treatment of life-threatening inflammatory conditions that are precipitated by Cytokine Storm Syndrome and not addressed with an approved therapy. Our mission is to save lives.

Sigyn Therapy™ is a novel blood purification technology designed to mitigate cytokine storm syndrome through the broad-spectrum depletion of inflammatory targets from the bloodstream. Cytokine storm syndrome is the hallmark of sepsis, which is the most common cause of in-hospital deaths and claims more lives each year than all forms of cancer combined. Virus induced cytokine storm (VICS) is associated with high mortality and is a leading cause of SARS-CoV-2 (COVID-19) deaths. Other therapeutic opportunities include, but are not limited to bacteria induced cytokine storm (BICS), acute respiratory distress syndrome (ARDS) and acute forms of liver failure, such as hepatic encephalopathy.

To learn more, visit www.SigynTherapeutics.com or www.SigynTherapy.com

Cautionary Note Regarding Forward-Looking Statements

This press release contains forward-looking statements of Sigyn Therapeutics, Inc. (“Sigyn”) that involve substantial risks and uncertainties. All statements contained in this press release are forward-looking statements within the meaning of The Private Securities Litigation Reform Act of 1995. The words “could,” “will,” “plan,” “intend,” “anticipate,” “approximate,” “expect,” “potential,” or the negative of these terms or other similar expressions are intended to identify forward-looking statements, although not all forward-looking statements contain these identifying words. These forward-looking statements include, among others, statements about Sigyn’s future financial performance, the impact of management changes, any proposed organizational restructuring, results of operations, capital resources to fund operations; statements about Sigyn’s expectations regarding the capitalization, resources and ownership structure of the combined company; statements about the potential benefits of the transaction; the expected completion and timing of the transaction and other information relating to the transaction; and any other statements other than statements of historical fact. Actual results or events could differ materially from the plans, intentions and expectations disclosed in the forward-looking statements that Sigyn makes due to a number of important factors, including (i) the risk that the transaction may not be completed in a timely manner or at all, which may adversely affect Sigyn’s business and the price of the common stock of Sigyn, (ii) the failure to satisfy of the conditions to the consummation of the transaction, (iii) the occurrence of any event, change or other circumstance that could give rise to the termination of the merger agreement, (iv) risks related to the ability to realize the anticipated benefits of the transaction, including the risk that the businesses will not be integrated successfully, (v) the effect of the announcement or pendency of the transaction on Sigyn’s business relationships, operating results and business generally, (vi) risks that the proposed transaction disrupts current plans and operations, (vii) risks related to the combined entity’s ability to up-list to a national securities exchange, (viii) risks related to the combined entity’s access to existing capital and fundraising prospects to fund its ongoing operations, (ix) risks related to diverting management’s attention from Sigyn’s ongoing business operations, (x) other business effects, including the effects of industry, market, economic, political or regulatory conditions, future exchange and interest rates, and changes in tax and other laws, regulations, rates and policies, and (xi) risks related to an inability to manufacture Sigyn Therapy, risks related to the clinical advancement of Sigyn Therapy with regulatory agencies, and no assurance that Sigyn Therapy will be proven to be a safe and efficacious treatment for any condition. The forward-looking statements in this press release represent Sigyn’s views as of the date of this press release. Sigyn anticipates that subsequent events and developments may cause its views to change. However, while it may elect to update these forward-looking statements at some point in the future, it specifically disclaims any obligation to do so. You should, therefore, not rely on these forward-looking statements as representing Sigyn’s views as of any date subsequent to the date of this press release.

Contact Sigyn Therapeutics, Inc.

Jim Joyce
Chairman, CEO
(619) 368-2000
[email protected]

Source: Sigyn Therapeutics, Inc.

Kiromic BioPharma (KRBP) Scheduled To Present at NobleCon17


Join Kiromic BioPharma (KRBP) CEO Maurizio Chiriva-Internati & CFO Tony Tontat at NobleCon17 – Noble Capital Markets 17th Annual Small & Microcap Investor Conference – January 19&20, 2021. Following a formal presentation, a seasoned Wall Street research analyst will join Maurizio and Tony to moderate a LIVE Q&A session. If you want to be added to the roster of presenters… or if you would like to join the virtual audience of investors, at no cost, go to nobleconference.com.

NobleCon 17 Complete Presenting Company Schedule

Helius Medical Technologies (HSDT) Scheduled To Present at NobleCon17


Join Helius Medical Technologies (HSDT) CEO Dane Andreeff at NobleCon17 – Noble Capital Markets 17th Annual Small & Microcap Investor Conference – January 19&20, 2021. Following a formal presentation, a seasoned Wall Street research analyst will join Dane to moderate a LIVE Q&A session. If you want to be added to the roster of presenters… or if you would like to join the virtual audience of investors, at no cost, go to nobleconference.com.

NobleCon 17 Complete Presenting Company Schedule

Esports Entertainment Group (GMBL) Scheduled To Present at NobleCon17


Join Esports Entertainment Group (GMBL) CEO Grant Johnson at NobleCon17 – Noble Capital Markets 17th Annual Small & Microcap Investor Conference – January 19&20, 2021. Following a formal presentation, a seasoned Wall Street research analyst will join Grant to moderate a LIVE Q&A session. If you want to be added to the roster of presenters… or if you would like to join the virtual audience of investors, at no cost, go to nobleconference.com.

NobleCon 17 Complete Presenting Company Schedule

Ely Gold Royalties (ELYGF)(ELY:CA) Scheduled To Present at NobleCon17


Join Ely Gold Royalties (ELYGF)(ELY:CA) CEO Trey Wasser at NobleCon17 – Noble Capital Markets 17th Annual Small & Microcap Investor Conference – January 19&20, 2021. Following a formal presentation, a seasoned Wall Street research analyst will join Trey to moderate a LIVE Q&A session. If you want to be added to the roster of presenters… or if you would like to join the virtual audience of investors, at no cost, go to nobleconference.com.

NobleCon 17 Complete Presenting Company Schedule

Capstone Turbine Corporation (CPST) Scheduled To Present at NobleCon17


Join Capstone Turbine (CPST) CEO Darren Jamison & CFO Eric Hencken at NobleCon17 – Noble Capital Markets 17th Annual Small & Microcap Investor Conference – January 19&20, 2021. Following a formal presentation, a seasoned Wall Street research analyst will join Darren and Eric to moderate a LIVE Q&A session. If you want to be added to the roster of presenters… or if you would like to join the virtual audience of investors, at no cost, go to nobleconference.com.

NobleCon 17 Complete Presenting Company Schedule

Rritual Superfoods Scheduled To Present at NobleCon17


Join Rritual Superfoods CEO David Kerbel & CMO Peter Palarchio at NobleCon17 – Noble Capital Markets 17th Annual Small & Microcap Investor Conference – January 19&20, 2021. Following a formal presentation, a seasoned Wall Street research analyst will join David and Peter to moderate a LIVE Q&A session. If you want to be added to the roster of presenters… or if you would like to join the virtual audience of investors, at no cost, go to nobleconference.com.

NobleCon 17 Complete Presenting Company Schedule

Release – Palladium One Mining (NKORF)(PDM:CA) – Massive Magmatic Sulphide Discovery at Tyko


Palladium One Massive Magmatic Sulphide Discovery Yields 8.7% Ni_Eq (193 lbs/tonne) over 3.8 Meters at Tyko

 

January 5, 2021 – Toronto, Ontario – The first two holes of the 2020 Tyko drill program intersected massive magmatic sulphides grading 8.7% Ni_Eq*(193 pounds per tonne) over 3.8 Meters (6.6% Ni, 3.7% Cu, 1.5g/t PGE) at less than 30 meters true-depth, at the Smoke Lake target of the Tyko Ni-Cu-PGE Project, in Ontario, Canada said Palladium One Mining (“Palladium One” or the “Company”) (TSXV: PDM, FRA: 7N11, OTC: NKORF) today. The current market price of nickel is approximately US$7.90 per pound.

Key Highlights:

  • Hole TK-20-016 returned 8.7% Ni_Eq(193 pounds per tonne) over 3.8 Meters (6.6% Ni, 3.7% Cu, 1.5g/t PGE) from 29.0 to 32.8 meters down hole.
    • Including 10.1% Ni_Eq (221 pounds per tonne) over 0.5 meters (8.2% Ni, 3.1% Cu, 1.5g/t PGE).
  • Hole TK-20-015, an up-dip hole, drilled from the same drill pad, returned 4.8% Ni_Eqover 2.3 meters (3.9% Ni, 1.4% Cu, 0.8g/t PGE) from 30 meters down hole.
    • Including 8.0% Ni_Eq over 1.0 meters (7.3% Ni, 0.8% Cu, 1.0g/t PGE).
  • All 13 holes drilled at Smoke Lake intersected magmatic sulphides with drilled widths ranging from 1 up to 15 meters.
    • Multiple massive sulphide intercepts up to 4 metres were encountered.
    • Assays for the remaining 11 holes are pending.
  • A magmatic sulphide mineralized strike length of 270 meters has been defined by drilling and the deepest intercept to date has a true depth of only 100 meters.
  • Mineralization remains open to the northwest and down dip.
  • Drilling suggests a shallow southwest dipping body which plunges to the west-northwest.

“We are very pleased with the extremely high-value, near surface resource potential at Smoke Lake. This is the first discovery of massive sulphide mineralization at the Tyko Ni-Cu-PGE Project and provides significant encouragement for additional discoveries given Tyko is woefully underexplored. The Tyko project covers over 20,000 hectares, which includes the 7,000 hectare mafic-ultramafic Bulldozer intrusion, which has seen virtually no geological mapping nor exploration” said Derrick Weyrauch, President and CEO.

The 2020 Tyko drill program consisted of 14 drill holes totalling 1,123 meters, 13 holes were drilled into the Smoke Lake electromagnetic (“EM”) anomaly. This program was the first to drill test the Smoke Lake EM anomaly (see press release January 21, 2020, December 7, 2020, November 18, 2020). High-resolution drone-based magnetic and ground-based horizontal loop EM surveys, undertaken shortly before drilling, refined the anomaly resulting in the successful discovery of massive magmatic sulphides. A bore hole EM survey is scheduled to be completed in January 2021 to further delineate the Smoke Lake massive sulphide body.

Drilling to date indicates a mineralized ultramafic body at surface, transitioning to massive sulphides which dip shallowly (~32°) to the southwest. The massive sulphides occur as a consistent sheet with a possible fault near its base which could be controlling their emplacement in tonalite.

The lithologies at Smoke Lake closely resemble those found at both the Tyko and RJ showings, located 17-kilometers to the west, which returned up to 1.06% Ni and 0.35% Cu over 6.22 m including 4.71% Ni and 0.82% Cu over 0.87 m in hole TK-16-010 (see press release June 8, 2016).

Table 1: Initial Tyko 2020 Drill Results from the Smoke Lake Discovery


(1) Reported widths are “drilled widths” not true widths.

Figure 1. Massive magmatic sulphide intersection in hole TK-20-016. Wall rock is tonalite.

Figure 2. Closeup of massive magmatic sulphide in hole TK-20-016

Figure 3. Plan map of the Smoke Lake area with 1st Vertical Mag as the background showing soil samples, as well as the axial traces of the two closely spaced ground based horizontal loop EM anomalies, and 2020 drill holes.

*Nickel Equivalent (“Ni_Eq”)
Nickel equivalent is calculated using US$1,100 per ounce for palladium, US$950 per ounce for platinum, US$1,300 per ounce for gold, US$6,614 per tonne (US$3.00 per pound) for copper, US$15,432 per tonne (US$7.00 per pound) for nickel and US$30,865 per tonne (US$14 per pound) for Cobalt. This calculation is consistent with the commodity prices used in the Company’s September 2019 NI 43-101 Kaukua resource estimate.

About Tyko Ni-Cu-PGE Project
The Tyko Ni-Cu-PGE Project, is located approximately 65 kilometers northeast of Marathon Ontario, Canada. Tyko is an early stage, high sulphide tenor, nickel focused project with the most recent drill hole intercepts returning up to 1.06% Ni over 6.22 m including 4.71% Ni over 0.87m in hole TK-16-010 (see press release dated June 8, 2016).

About Tyko Ni-Cu-PGE Project
The Tyko Ni-Cu-PGE Project, is located approximately 65 kilometers northeast of Marathon Ontario, Canada. Tyko is an early stage, high sulphide tenor, nickel focused project with the most recent drill hole intercepts returning up to 1.06% Ni over 6.22 m including 4.71% Ni over 0.87m in hole TK-16-010 (see press release dated June 8, 2016).

Qualified Person

The technical information in this release has been reviewed and verified by Neil Pettigrew, M.Sc., P. Geo., Vice President of Exploration and a director of the Company and the Qualified Person as defined by National Instrument 43- 101.

About Palladium One

Palladium One Mining Inc. is an exploration company targeting district scale, platinum-group-element (PGE)-coppernickel deposits in Finland and Canada. Its flagship project is the Läntinen Koillismaa or LK Project, a palladiumdominant platinum group element-copper-nickel project in north-central Finland, ranked by the Fraser Institute as one of the world’s top countries for mineral exploration and development. Exploration at LK is focused on targeting disseminated sulfides along 38 kilometers of favorable basal contact and building on an established NI 43-101 open pit resource.

ON BEHALF OF THE BOARD
“Derrick Weyrauch”
President & CEO, Director

For further information contact:
Derrick Weyrauch, President & CEO
Email:
[email protected]

Neither the TSX Venture Exchange nor its Market Regulator (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.

This press release is not an offer or a solicitation of an offer of securities for sale in the United States of America. The common shares of Palladium One Mining Inc. have not been and will not be registered under the U.S. Securities Act of 1933, as amended, and may not be offered or sold in the United States absent registration or an applicable exemption from registration.

Information set forth in this press release may contain forward-looking statements. Forward-looking statements are statements that relate to future, not past events. In this context, forward-looking statements often address a company’s expected future business and financial performance, and often contain words such as “anticipate”, “believe”, “plan”, “estimate”, “expect”, and “intend”, statements that an action or event “may”, “might”, “could”, “should”, or “will” be taken or occur, or other similar expressions. By their nature, forward-looking statements involve known and unknown risks, uncertainties and other factors which may cause our actual results, performance or achievements, or other future events, to be materially different from any future results, performance or achievements expressed or implied by such forward-looking statements. Such factors include, among others, risks associated with project development; the need for additional financing; operational risks associated with mining and mineral processing; fluctuations in palladium and other commodity prices; title matters; environmental liability claims and insurance; reliance on key personnel; the absence of dividends; competition; dilution; the volatility of our common share price and volume; and tax consequences to Canadian and U.S. Shareholders. Forward-looking statements are made based on management’s beliefs, estimates and opinions on the date that statements are made and the Company undertakes no obligation to update forward-looking statements if these beliefs, estimates and opinions or other circumstances should change. Investors are cautioned against attributing undue certainty to forward-looking statements.

Source: Palladium One Mining Inc.

Vectrus (VEC) – A Busy Holiday Period for Vectrus Another Acquisition

Tuesday, January 05, 2021

Vectrus (VEC)
A Busy Holiday Period for Vectrus: Another Acquisition

Vectrus Inc is a U.S.-based company that provides services to the U.S. government. It operates as one segment and offer facility and logistics services and information technology and network communications services. The information technology and network communications capabilities consist of communications systems operations and maintenance, management and service support, systems installation and activation, system-of-systems engineering and software development, and mission support for the department of defense. The facility and logistics service include airfield management, ammunition management, civil engineering, communications, emergency services, life support activities, public works, security, transportation operations and others.

Joe Gomes, Senior Research Analyst, Noble Capital Markets, Inc.

Refer to the full report for the price target, fundamental analysis, and rating.

    HHB Systems. Monday morning, Vectrus announced its second acquisition in a week, this time acquiring HHB Systems. HHB Systems is a leading provider of high-end solutions for facilities management, logistics, engineering, enterprise operations, and asset management solutions supporting Intelligence Community (IC) projects. Additionally, HHB provides information technology and cybersecurity solutions to select clients. Financial details of the acquisition were not released.

    HHB Benefits.  HHB advances Vectrus’ ability to deliver innovative, integrated solutions and further differentiates the company as a leader in the converged infrastructure market, in our view. According to Vectrus, the Zenetex and HHB teams work together in the IC market today and expand the opportunities under Vectrus to reach existing DoD and IC clients …



This Company Sponsored Research is provided by Noble Capital Markets, Inc., a FINRA and S.E.C. registered broker-dealer (B/D).

*Analyst certification and important disclosures included in the full report. NOTE: investment decisions should not be based upon the content of this research summary.  Proper due diligence is required before making any investment decision. 

Gevo, Inc. (GEVO) – Two milestones in a week – FEED Engineering firm identified

Tuesday, January 05, 2021

Gevo, Inc. (GEVO)
Two milestones in a week – FEED Engineering firm identified

Gevo Inc is a renewable chemicals and biofuels company engaged in the development and commercialization of alternatives to petroleum-based products based on isobutanol produced from renewable feedstocks. Its operating segments are the Gevo segment and the Gevo Development/Agri-Energy segment. By its segments, it is involved in research and development activities related to the future production of isobutanol, including the development of its biocatalysts, the production and sale of biojet fuel, its Retrofit process and the next generation of chemicals and biofuels that will be based on its isobutanol technology. Gevo Development/Agri-Energy is the key revenue generating segment which involves the operation of the Luverne Facility and production of ethanol, isobutanol and related products.

Poe Fratt, Senior Research Analyst, Noble Capital Markets, Inc.

Refer to the full report for the price target, fundamental analysis, and rating.

    Another milestone hit with identification of FEED firm. Koch Project Solutions, LLC is performing front end engineering, design and project execution management services (FEED) for the renewable fuel expansion projects. Koch Project Solutions is part of a subsidiary of Koch Industries. Like Trafigura, the new relationship could open up collaboration opportunities on other fronts. While there is no indication that other subs are involved, establishing a relationship with a major energy industry player should be viewed as a positive development.

    Debt free milestone hit.  Strong December stock price performance was catalyst for debt conversion into equity. Last week, we learned from an ATM equity prospectus update that all of the convert debt was converted into equity. A total of 5.67 million shares were issued to Whitebox, and ~$14 million of cash was preserved to keep current cash near $79 million …



This Company Sponsored Research is provided by Noble Capital Markets, Inc., a FINRA and S.E.C. registered broker-dealer (B/D).

*Analyst certification and important disclosures included in the full report. NOTE: investment decisions should not be based upon the content of this research summary.  Proper due diligence is required before making any investment decision. 

Ayala Pharmaceuticals (AYLA) – Pivotal Desmoid Tumor Trial is Set to Initiate in H1 2021

Tuesday, January 05, 2021

Ayala Pharmaceuticals (AYLA)
Pivotal Desmoid Tumor Trial is Set to Initiate in H1 2021

Ayala Pharmaceuticals Inc clinical-stage oncology company focused on developing and commercializing small molecule therapeutics for patients suffering from rare and aggressive cancers, primarily in genetically defined patient populations. The company’s current portfolio of product candidates, AL101 and AL102, targets the aberrant activation of the Notch pathway with gamma secretase inhibitors. Its product candidate, AL101, is being developed as a potent, selective, injectable small molecule gamma secretase inhibitor, or GSI. It is also developing AL101 for the treatment of T-ALL, an aggressive, rare form of T-cell specific leukemia.

Ahu Demir, Ph. D., Biotechnology Research Analyst, Noble Capital Markets, Inc.

Refer to the full report for the price target, fundamental analysis, and rating.

    Ayala receives the green light to proceed with a Phase 2/3 pivotal study for desmoid tumor. Yesterday, Ayala announced that the U.S. Food and Drug Administration (FDA) agreed to allow Ayala to proceed with a Phase 2/3 study, which can potentially be a registration-enabling pivotal trial, evaluating AL102 for the treatment of desmoid tumors.

    What is next?.  The company intends to commence Phase 2/3 RINGSIDE study in adult and adolescent patients with desmoid tumors in H1 2021. RINGSIDE study will include two parts: Part 1 to enroll 36 patients assessing 3 doses of AL102 and Part 2 to use a double-blind placebo-controlled section enrolling up to 156 patients. The interim data read-out from Part 1 and dose selection is expected by …



This Company Sponsored Research is provided by Noble Capital Markets, Inc., a FINRA and S.E.C. registered broker-dealer (B/D).

*Analyst certification and important disclosures included in the full report. NOTE: investment decisions should not be based upon the content of this research summary.  Proper due diligence is required before making any investment decision.